$LTRN What happens in June?
Lantern Pharma has announced a dedicated June webcast focused on withZeta, its AI platform business.
The most important question isn’t about the pipeline.
It’s whether management starts presenting Lantern as more than a biotech company.
Will we hear about:
• Paying customers?
• Subscription revenue?
• Strategic partnerships?
• A spin-off or independent entity for withZeta?
• A roadmap to commercialize the platform?
If withZeta is positioned as a standalone business, June could mark the beginning of a major shift in how the market values Lantern.
The drugs may be the proof of concept.
The platform may be the real story.